<DOC>
	<DOCNO>NCT00332904</DOCNO>
	<brief_summary>The studyÂ´s purpose investigate effect beta blockade aldosterone antagonist therapy oxygenation , peripheral cardiac hemodynamics humoral system , patient liver cirrhosis .</brief_summary>
	<brief_title>Effect Betablocker Aldosterone Antagonist Therapy Patients With Liver Cirrhosis</brief_title>
	<detailed_description>Cardio-pulmonal complication patient liver cirrhosis portal hypertension determine patient ' prognosis . Most patient hemodynamical change circulation increase cardiac output decrease systolic function stress . Endothelial dysfunction parameter bad prognosis cardiovascular disease . The Renin-angiotensin-aldosterone-system play important role natrium volume regulation . Descriptions change peripheral circulation oxygenation deficient . Patients liver cirrhosis portal hypertension betablockers and/or aldosterone antagonist routine treatment - effect peripheral hemodynamics oxygenation relation central hemodynamic change deficient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Liver cirrhosis Clinical indication treatment betablocker aldosterone antagonist Must treat earlier betablocker aldosterone antagonist Must alcohol abstinent 4 week Gastrointestinal bleeding last 2 week Encephalopathy &gt; grade 1 Acute medical condition Malignant disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>betablocker</keyword>
	<keyword>aldosterone antagonist</keyword>
	<keyword>peripheral haemodynamics</keyword>
	<keyword>cardiac haemodynamics</keyword>
	<keyword>oxygenation</keyword>
</DOC>